BNP/CALL/BRISTOL-MYERS SQUIBB/65/0.1/20.12.24 | Delayed Deutsche Boerse AG 02:20:46 2024-07-09 am EDT | ||
| 0.006 EUR | 0.00% |
|
| Current month | -25.00% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-09 | 0.006 | 0.00% |
| 24-07-08 | 0.006 | 0.00% |
| 24-07-05 | 0.006 | 0.00% |
| 24-07-04 | 0.006 | +500.00% |
| 24-07-03 | 0.001 | -80.00% |
Delayed Quote Deutsche Boerse AG
Last update July 09, 2024 at 02:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE8956 |
| ISIN | DE000PE89562 |
| Date issued | 2023-02-16 |
| Strike | 65 $ |
| Maturity | 2024-12-20 (165 Days) |
| Parity | 10 : 1 |
| Emission price | 1.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.085 € |
| Spread % | 93.41% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
39.99
USD
Average target price
53.19
USD
Spread / Average Target
+33.02%
- Stock Market
- Warrants
- Warrant
